Quarterly report pursuant to Section 13 or 15(d)

Segment information

v2.3.0.15
Segment information
3 Months Ended
Sep. 30, 2011
Segment information

I. Segment information:

The Company has two reportable segments based on the nature of products: biotechnology and hematology. Following is financial information relating to the Company’s reportable segments (in thousands):

 

     Quarter Ended
September 30,
 
     2011     2010  

External sales

    

Biotechnology

   $ 72,303      $ 63,041   

Hematology

     5,293        4,904   
  

 

 

   

 

 

 

Consolidated net sales

   $ 77,596      $ 67,945   
  

 

 

   

 

 

 

Earnings before income taxes

    

Biotechnology

   $ 39,984      $ 38,460   

Hematology

     1,918        1,922   
  

 

 

   

 

 

 

Segment earnings before income taxes

     41,902        40,382   

Unallocated corporate expenses and equity method investee losses

     (1,402     (1,429
  

 

 

   

 

 

 

Consolidated earnings before income taxes

   $ 40,500      $ 38,953